Meniere's disease is a type of disorder that causes congestion in the ear, hearing loss, dizziness (also known as vertigo), and ringing in the ears (also known as tinnitus). In some cases, patients fall due to severe vertigo and such sort of attack called drop attacks. It has been observed that meniere’s disease occurs mostly between 40 to 60 years of age. Meniere's disease is caused by fluid build-up in the labyrinth which comprises of two parts, including the membranous labyrinth and bony labyrinth. Membranous labyrinth is filled with a fluid known as endolymph. Building-up of endolymph causes anomalies in hearing signals and normal balance which further leads to vertigo. Sound Pharmaceuticals, Inc. is in the process of developing SPI-1005 as an antioxidant for the treatment of meniere’s disease. Otonomy, Inc. is in the process of developing OTIVIDEX (dexamethasone) as a glucocorticoid receptor agonist for the treatment of meniere’s disease. Some of the companies having the pipeline of meniere’s disease include Sound Pharmaceuticals, Inc., Otonomy, Inc., Xenon Pharmaceuticals Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.